To evaluate the diagnostic significance of GLRX3 compared with CA19–9, we examined GLRX3 by enzyme-linked immunosorbent assay (ELISA) in 70 individual serum samples from normal healthy individuals (n = 10; 6 males and 4 females; median age 47.5-year old with range 40 ~ 63) and from patients with pancreatic cancer (n = 60, details in Additional file 1: Table S4). This evidence concerns the gene GLRX3 and pancreatic neoplasm.